

WY-DUR
Wyoming Drug Utilization Review Board
Dept. 3375
1000 E. University Avenue
Laramie, WY 82071
307-766-6750

Aimee Lewis, Pharm.D.
DUR Manager
Kurt Hopfensperger, M.D., J.D.
Chair
Rebecca Ormas, R.Ph.
Vice Chair

October 1, 2009

Dear Prescriber:

Last April, the Preferred Drug List Advisory Committee reviewed the ophthalmic prostaglandin agonists. At that time, the Committee noted that the available evidence showed no significant difference among these agents. As a result, this class will be added to the Preferred Drug List.

The Wyoming Drug Utilization Review Board is charged with development of prior authorization criteria to address the utilization of medications in the Wyoming Medicaid program. As a part of this process, the Board is asking you to participate in an effort to enlist the expertise of practitioners affected by the following criteria recently drafted by the Board.

Ophthalmic prostaglandin criteria
September 24, 2009

Preferred agents: Travatan and Lumigan

Non-preferred agent: Xalatan

Criteria for non-preferred: Trial and failure of both preferred agents.

Please provide comments on the listed criteria by October 30, 2009 to my attention at the University of Wyoming School of Pharmacy address provided above. Your participation and guidance to the WY-DUR Board are invaluable and I would like to thank you for taking the time to review the information.

Sincerely,

Aimee Lewis

Aimee Lewis, Pharm.D.
WY-DUR Program Manager